Close Menu

NEW YORK – Dante Labs announced Tuesday its Immensa software received CE-IVD marking for the interpretation of whole-genome sequencing data in a clinical setting at scale.

The software generates personalized reports for pharmacogenomics, rare diseases, predisposition to common diseases, and nutrigenomics, and integrates guidelines from the American College of Medical Genetics, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.